| Market Capitalization (Millions $) |
509 |
| Shares
Outstanding (Millions) |
291 |
| Employees |
135 |
| Revenues (TTM) (Millions $) |
164 |
| Net Income (TTM) (Millions $) |
-372 |
| Cash Flow (TTM) (Millions $) |
-59 |
| Capital Exp. (TTM) (Millions $) |
11 |
Iovance Biotherapeutics Inc
Iovance Biotherapeutics Inc is a biotechnology company that specializes in developing and commercializing life-saving cell therapies. They focus on the development of tumor-infiltrating lymphocyte (TIL) therapies, which involve the extraction of a patient's own immune cells, expanding and activating them in the lab, and then infusing them back into the patient to target and fight cancer cells.
The company's TIL therapies have shown promising results in clinical trials, particularly in patients with advanced melanoma. Iovance Biotherapeutics aims to provide personalized cancer treatments using TIL therapies as a potential alternative to traditional approaches like chemotherapy.
They have a dedicated team of scientists, researchers, and clinicians who work towards advancing their TIL therapies and expanding their pipeline to target different types of cancer. Additionally, the company collaborates with various academic and industry partners to leverage cutting-edge technology and expertise in their research and development efforts.
Iovance Biotherapeutics Inc operates globally and is committed to improving the lives of cancer patients by delivering innovative cell therapies that harness the power of the immune system to fight cancer.
Company Address: 825 Industrial Road, Suite 100 San Carlos 94070 CA
Company Phone Number: 260-7120 Stock Exchange / Ticker: NASDAQ IOVA
|
8.66% 
98.74 %